1. Home
  2. PRME vs UPBD Comparison

PRME vs UPBD Comparison

Compare PRME & UPBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

N/A

Current Price

$3.97

Market Cap

526.0M

Sector

Health Care

ML Signal

N/A

Logo Upbound Group Inc.

UPBD

Upbound Group Inc.

N/A

Current Price

$15.30

Market Cap

1.1B

ML Signal

N/A

Company Overview

Basic Information
Metric
PRME
UPBD
Founded
2019
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
526.0M
1.1B
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
PRME
UPBD
Price
$3.97
$15.30
Analyst Decision
Buy
Buy
Analyst Count
14
6
Target Price
$7.11
★ $28.08
AVG Volume (30 Days)
★ 4.0M
959.4K
Earning Date
11-06-2026
10-29-2026
Dividend Yield
N/A
★ 9.94%
EPS Growth
★ 18.18
N/A
EPS
N/A
★ 0.98
Revenue
$4,632,000.00
★ $4,695,061,000.00
Revenue This Year
$90.65
$0.80
Revenue Next Year
$19.47
$4.05
P/E Ratio
★ N/A
$16.01
Revenue Growth
★ 55.28
8.67
52 Week Low
$2.67
$14.98
52 Week High
$6.65
$23.98

Technical Indicators

Market Signals
Indicator
PRME
UPBD
Relative Strength Index (RSI) 63.75 28.89
Support Level $2.88 N/A
Resistance Level $4.03 $16.31
Average True Range (ATR) 0.34 0.55
MACD 0.10 0.02
Stochastic Oscillator 87.96 14.17

Price Performance

Historical Comparison
PRME
UPBD

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions, Mexico segment offers lease-to-own stores in Mexico. The The Brigit segment offers various financial health products and tools to help users improve their financial health. The company derives a majority of its revenue from the Acima segment.

Share on Social Networks: